Try our Advanced Search for more refined results
Ixchel Pharma, LLC. v. Biogen Inc.
January 26, 2018
A California federal judge on Thursday gave Ixchel Pharma LLC one last chance to accuse Biogen Inc. of entering into an anti-competitive agreement with another company and undermining Ixchel's development of a treatment for a rare neuromuscular disease, holding the latest complaint is just as deficient as its predecessor.
September 12, 2017
A California federal judge on Tuesday dismissed Ixchel Pharma LLC's claims alleging Biogen Inc. made an anti-competitive agreement to undermine Ixchel's development of a treatment for a rare neuromuscular disease, saying the two companies are not competitors.
August 14, 2017
Ixchel Pharma LLC on Friday told a California federal court it had already suffered financial losses due to rival Biogen Inc.'s alleged anti-competitive scheme to undermine its development of a treatment for a rare neuromuscular disease and asked that its lawsuit be allowed to proceed.
May 25, 2017
Biogen Inc. asked a California federal judge to toss an antitrust suit brought by a pharmaceutical research company, arguing Wednesday that the company failed to show how Biogen's decision to enter a patent settlement and license agreement caused any harm to competition.
April 04, 2017
Biogen Inc. is facing an antitrust suit in California federal court filed Tuesday by Ixchel Pharma LLC alleging it attempted to hold a monopoly on drug treatments containing dimethyl fumarate, preventing Ixchel from creating a drug for a degenerative neurological disease.